Background Serotonin 5-HT 2A and metabotropic glutamate 2 (mGlu2) are neurotransmitter G protein-coupled receptors (GPCRs) involved in the signaling mechanisms underlying psychosis and schizophrenia treatment. Previous findings in mGlu2 knockout (KO) mice suggested that mGlu2 is necessary for head-twitch behavior, a rodent phenotype characteristic of hallucinogenic 5-HT 2A receptor agonists. However, the role of mGlu2 in the behavioral effects induced by antipsychotic drugs remains poorly understood. Here, we tested antipsychotic-like behavioral phenotypes induced by the atypical antipsychotic clozapine in mGlu2-KO mice and wild-type control littermates. Methods Locomotor activity was tested in mGlu2-KO mice and control littermates injected (i.p.) with clozapine (1.5 mg/kg) or vehicle followed by MK801 (0.5 mg/kg), PCP (7.5 mg/kg), amphetamine (6 mg/kg), scopolamine (2 mg/kg), or vehicle. Using a virally (HSV) mediated transgene expression approach, the role of frontal cortex mGlu2 in the modulation of MK801-induced locomotor activity by clozapine treatment was also evaluated. Results The effect of clozapine on hyperlocomotor activity induced by the dissociative drugs MK801 and phencyclidine (PCP) was decreased in mGlu2-KO mice as compared to controls. Clozapine treatment, however, reduced hyperlocomotor activity induced by the stimulant drug amphetamine and the deliriant drug scopolamine in both wild-type and mGlu2-KO mice. Virally mediated over-expression of mGlu2 in the frontal cortex of mGlu2-KO mice rescued the ability of clozapine to reduce MK801-induced hyperlocomotion. Conclusion These findings further support the existence of a functionally relevant crosstalk between 5-HT 2A and mGlu2 receptors in different preclinical models of antipsychotic activity.
Introduction
Schizophrenia, as currently defined, represents a unique human disorder, and modeling schizophrenia-related phenotypes in rodents remains challenging (Arguello and Gogos 2006; Fernando and Robbins 2011; Jones et al. 2011) . Despite displaying very distinct pharmacological profiles, stimulant drugs such phencyclidine (PCP) and MK801 (noncompetitive NMDA receptor antagonists) (Malhotra et al. 1997; Umbricht et al. 2000; Umbricht et al. 2002) , amphetamine (which, among other mechanisms, derives its psychoactive effects through augmentation of dopamine efflux via the dopamine transporter) (Featherstone et al. 2007; Bramness et al. 2012) , and scopolamine (non-specific muscarinic Kelsey S. Hideshima and Ashkhan Hojati contributed equally to this work. receptor antagonist) (Young et al. 2013; Ham et al. 2017) induce behavioral disruptions in healthy subjects that present certain similarities with those observed in schizophrenia patients (Steeds et al. 2015) . Some of these disruptive behaviors and their prevention with antipsychotics have been successfully reproduced in animal models. For instance, modulation of hyperlocomotor activity induced by MK801 has already been validated as an assay for detection of antipsychotic action (Bradford et al. 2010) .
Despite bearing a complex polypharmacology (Meltzer 2013) , clozapine and other atypical antipsychotics, such as olanzapine and risperidone, possess a very high affinity for the serotonin 5-HT 2A receptor, alongside with a lower affinity for the dopamine D 2 receptor (Lieberman et al. 2008; Miyamoto et al. 2012) . Based on assays in heterologous expression systems such as NIH-3T3 and COS-7 cells, it was postulated that atypical antipsychotics share a pharmacological property: inverse agonism for the 5-HT 2A receptor (Sullivan et al. 2015) . More recent findings suggest that clozapine also behaves as a partial agonist activating certain signaling pathways downstream of the 5-HT 2A receptor, such as Akt phosphorylation (Schmid et al. 2014) . Long-lasting exposure to clozapine induces 5-HT 2A receptor internalization in tissue culture (Bhatnagar et al. 2001; Raote et al. 2013 ) and downregulation of frontal cortex 5-HT 2A receptor density in rodent models (Yadav et al. 2011; Moreno et al. 2013; Ibi et al. 2017) . These processes of 5-HT 2A receptor internalization and downregulation after chronic exposure to clozapine treatment have been postulated to be one of the possible mechanisms underlying clozapine's antipsychotic action. Nevertheless, in schizophrenia patients, many clinical studies show improvement hours/days immediately after antipsychotic drug administration (Agid et al. 2003) . This underscores the need for further research into the basic mechanisms underlying acute therapeutic effects upon antipsychotic drug administration.
The serotonin 5-HT 2A receptor is responsible for most of the signaling and psychoactive effects induced by hallucinogenic drugs (also termed psychedelics), such as lysergic acid diethylamide (LSD), psilocin, and mescaline (Nichols 2004 (Nichols , 2016 . Rodent behavior models of hallucinogenic drug action, such as head-twitch behavior (Hanks and Gonzalez-Maeso 2013) , are blocked by 5-HT 2A receptor antagonists (Willins and Meltzer 1997; Fantegrossi et al. 2010 ). This hallucinogendependent behavioral phenotype is also abolished in 5-HT 2A knockout (KO) mice (Gonzalez-Maeso et al. 2003; GonzalezMaeso et al. 2007) . Similar findings supporting a role for 5-HT 2A receptor-dependent signaling processes in the mechanism of action of hallucinogens have been reported in humans. Thus, the psychedelic effects of LSD and psilocin are blocked by the 5-HT 2A receptor antagonist ketanserin in healthy volunteers (Vollenweider et al. 1998; Schmid et al. 2015; Preller et al. 2017) . Our previous findings suggested that the 5-HT 2A receptor-dependent head-twitch behavior induced by the hallucinogens DOI and LSD is significantly reduced in mGlu2-KO mice as compared to wild-type littermates )-this notion has recently been supported by the demonstration that administration of the hallucinogenic 5-HT 2A receptor agonist DOI elicited a dose-dependent headtwitch behavioral effect in wild-type mice, a phenotype that was abolished in mGlu2-KO, but not in mGlu3-KO, mice (Benvenga et al. 2018) .
Additionally, our previous findings demonstrated that the ability of clozapine to prevent MK801-induced hyperlocomotor activity was significantly decreased in mGlu2-KO mice (Fribourg et al. 2011) . These results suggested that the mGlu2 receptor is necessary to induce certain 5-HT 2A receptordependent antipsychotic-related behavioral phenotypes. However, it remains unsolved whether the mGlu2 receptor plays a role in the psychosis-like behaviors induced by PCP, amphetamine, and scopolamine in rodents or in the blockade of these phenotypes by antipsychotics.
G protein-coupled receptors (GPCRs) were assumed to exist and function as monomeric structural units. However, more recent findings suggest that GPCRs may be assembled as homomeric and/or heteromeric protein complexes under certain experimental conditions (Gonzalez-Maeso 2011 , 2014 . We and others have shown a laminar co-distribution of 5-HT 2A and mGlu2 in layers II/II and Vof the frontal cortex that is not apparent in other cortical and subcortical regions (Marek et al. 2000; Gonzalez-Maeso et al. 2008) . Additionally, we previously reported that 5-HT 2A and mGlu2 receptors form a highly specific GPCR heteromeric complex in living mammalian cells (Gonzalez-Maeso et al. 2008; Fribourg et al. 2011; Moreno et al. 2012; Baki et al. 2016; Moreno et al. 2016) .
In the present study, we tested the role of the mGlu2 receptor in repression of hyperlocomotor activity induced by a battery of psychoactive drugs upon clozapine administration. Using a virally (HSV) mediated over-expression approach, we also tested whether frontal cortex mGlu2 expression is sufficient to modulate the effect of clozapine treatment on MK801-induced hyperlocomotor activity. This was performed in parallel with HSV-mediated over-expression of an mGlu2/mGlu3 chimeric construct that, based on our previous findings in heterologous expression systems , is unable to form a GPCR heteromeric complex with the 5-HT 2A receptor.
Methods

Animals
Experiments were performed on adult (10-20 weeks old) male mice. Animals were housed at 12 h light/dark cycle at 23°C with food and water ad libitum, except during behavioral testing. Experiments were conducted in accordance with NIH guidelines and were approved by the Virginia Commonwealth University Animal Care and Use Committee. All efforts were made to minimize animal suffering and the number of animals used. mGlu2 knockout (KO) mice have been described previously (Yokoi et al. 1996; Moreno et al. 2011) . For experiments involving mGlu2-KO mice, wild-type littermates in the 129S6/Sv background were used as controls. All subjects were offspring of heterozygote breeding.
Behavioral testing took place between 9:00 a.m. and 6:00 p.m. Each behavioral paradigm was separated at least 1 week for a wash-out period.
Materials and drug administration
, and scopolamine were purchased from Sigma-Aldrich. Clozapine was obtained from Tocris. DOI, MK801, PCP, and scopolamine were injected (i.p.) after suspension in a minimal amount of DMSO and made up to volume with normal saline. Clozapine was injected (i.p.) after dissolution in a minimal volume of DMSO supplemented with acetic acid and made up to volume with normal saline. The injected doses were as follows: DOI, 1 mg/kg; clozapine, 1.5 mg/kg; MK801, 0.5 mg/kg; PCP, 7.5 mg/kg; amphetamine, 6.0 mg/kg; and scopolamine, 2 mg/kg. Doses of DOI and MK801 were selected based on previous studies (Gonzalez-Maeso et al. 2007; Fribourg et al. 2011; Moreno et al. 2011; Kurita et al. 2012; Ibi et al. 2017) . Doses of PCP, amphetamine, and scopolamine were selected based on previous studies (Fell et al. 2008; Woolley et al. 2008; Lavreysen et al. 2015) and on pilot dose-response assays (data not shown). The dose of clozapine (1.5 mg/kg) was selected based on our previous findings with dose-response assays with which we demonstrated that the effect of clozapine (1.5 mg/kg) on MK801-induced hyperlocomotor activity was absent in 5-HT 2A -KO mice (Fribourg et al. 2011) , whereas the effect of higher doses of clozapine on MK801-induced hyperlocomotor activity were observed in both wild-type and 5-HT 2A -KO mice (Fribourg et al. 2011) . Vehicletreated mice received 0.9% saline (0.1 ml/g body weight).
Locomotor behavior
Motor function (exploratory behavior) was assessed using a computerized three-dimensional activity monitoring system (Omnitech). The system determines motor activity based on frequency of interruptions to infrared beams traversing the x, y, and z planes. For basal locomotor activity, mice were monitored for 90 min (dimensions of the arena 27 × 27 × 21 cm). For center time, the proportion of time spent in the center of the arena was interpreted as a measure of anxiety (dimensions of the arena 41 × 41 × 30 cm). For modulation of locomotor activity post-drug administration, mice first were left to habituate in the locomotor box (dimensions of the arena 27 × 27 × 21 cm) for 90 min, during which mice were able to explore the test chamber to mitigate novelty-induced effects. After habituation, mice were injected (i.p.) with clozapine or vehicle. A 5-min lag in the test chamber followed (not shown in the analysis), after which MK801, PCP, amphetamine, or scopolamine were administered (i.p.). Mice were monitored for an additional 120-min period during the test phase. Locomotor activity was automatically determined from the interruptions of beams in the horizontal and vertical planes. All locomotor behavior experiments were carried out at 16 lx. Time blocks to test locomotor activity upon administration of psychoactive drugs (MK801, PCP, and amphetamine 20-80 min and 85-120 min; scopolamine 5-80 min and 85-120 min) were selected based on pilot assays that evaluated the temporal phases in which clozapine (1.5 mg/kg) affects hyperlocomotor activity (data not shown).
Virally mediated over-expression
The constructs mGlu2 and mGlu2ΔTM4N, in which the intracellular end of TM4 of mGlu2 is replaced with the intracellular end of TM4 of mGlu3, subcloned into a bicistronic HSV-GFP vector have been described before . HSV-mGlu2, HSV-mGlu2ΔTM4N, or control HSV-GFP was injected into the frontal cortex by stereotaxic surgery according to standard methods (Kurita et al. 2012; Moreno et al. 2012; Ibi et al. 2017) . Mice were anesthetized with a combination of ketamine (100 mg/kg) and xylazine (10 mg/kg) during the surgery. The virus was delivered bilaterally with a Hamilton syringe at a rate of 0.1 μl/min for a total volume of 0.5 μl on each side. The following coordinates were used: + 1.6 mm rostral-caudal, − 2.4 mm dorsal-ventral, and + 2.6 mm medial-lateral from bregma (relative to dura) with a 10°lateral angle. The coordinates were taken according to a published atlas of the 129/Sv mouse strain (Hof et al. 2000) . The Nissl staining patterns of the coronal brain slice were taken from the mouse brain atlas with author's permission. All experiments were performed 3-4 days after the viral infection, when transgene expression is maximal. Virally mediated mGlu2 and mGlu2ΔTM4N over-expression levels in frontal cortex have previously been confirmed by Western blotting ).
Immunohistochemistry
Immunohistochemistry assays were performed as previously reported with minor changes (Kurita et al. 2012; Moreno et al. 2012 ). The animals were deeply anesthetized with a combination of ketamine (100 mg/kg) and xylazine (10 mg/kg) prior to the surgery. Transcardiac perfusion was performed with 10 ml PBS, followed by 30 ml of freshly prepared 4% paraformaldehyde (PFA) in PBS at room temperature. Brains were removed and immersion-fixed in 4% PFA in PBS at 4°C (overnight) and stored at 30% sucrose in PBS for at least 48 h at 4°C. Screening of immunoreactive cells used a series of 20 μm-thick coronal sections from frontal cortex prepared on a sliding vibratome (Leica VT1000S). The free-floating sections were transferred to 24-well dishes containing PBS. Coronal brain sections were washed with PBS and incubated in 5% bovine serum albumin with 0.1% Triton X-100 in PBS for 60 min at 4°C. The sections were then incubated overnight in the same solution containing the anti-GFP antibody (Invitrogen A11122; 1:1000). The sections were rinsed five times in PBS for 10 min and incubated for 1 h with Alexa 488 dye-conjugated goat anti-rabbit antibody (1:2000) . Following incubation, the sections were washed three times with PBS, and the immunostained sections were examined by epifluorescence microscopy (AxioImager Z1, Carl Zeiss).
Statistical analysis
Statistical analyses were performed with GraphPad Prism software version 6. No statistical methods were used to predetermine sample sizes, but our sample sizes are similar to those reported in our previous publications. Data distribution was assumed to be normal but this was not formally tested. Animals were randomly allocated into the different experimental groups. Statistical significance of experiments involving three or more groups and two or more treatments was assessed by two-way ANOVA followed by Bonferroni's post hoc test. Statistical significance of experiments involving three or more groups was assessed by one-way ANOVA followed by Bonferroni's post hoc test. Statistical significance of experiments involving two groups was assessed by Student's t test. The level of significance was chosen at P = 0.05. All values included in the figure legends represent mean ± SEM.
Results
Exploratory behavior
Two-way ANOVA revealed that there was a significant effect of genotype on spontaneous locomotor activity (exploratory behavior) (Fig. 1a) (F 1,43 = 7.60; P < 0.01). Summation of horizontal activity from t = 5 to t = 30 min was increased in mGlu2-KO mice as compared to wild-type littermates ( Fig.  1b ) (t 43 = 2.91; P < 0.01). Summation of horizontal activity from t = 35 to t = 85 min was also increased in mGlu2-KO mice as compared to wild-type littermates (Fig. 1c ) (t 43 = 2.26; P < 0.05).
Two-way ANOVA revealed that there was trend toward an effect of genotype on center time ( Fig. 1d ) (F 1,9 = 3.69; P = 0.08). The trend for augmented center time from t = 5 to t = 30 min was also evident in mGlu2-KO mice as compared to wild-type littermates ( Fig. 1e ) (t 9 = 2.47; P < 0.05). Summation of horizontal activity from t = 35 to t = 85 min was unaffected in mGlu2-KO mice as compared to wild-type littermates ( Fig. 1f ) (t 9 = 0.15; P > 0.05).
Effect of the hallucinogen DOI on locomotor activity
Two-way ANOVA revealed that there was a significant effect of DOI treatment on locomotor activity time course from t = 20 to t = 120 min in wild-type mice ( Fig. 2a ) (F 1,16 = 11.16; P < 0.01). Two-way ANOVA revealed that there was not a significant effect of DOI treatment on locomotor activity time course from t = 20 to t = 120 min in mGlu2-KO mice ( Two-way ANOVA also indicated that there was not a significant effect of DOI treatment on summation of locomotor activity from t = 20 to t = 80 min ( Fig. 2c ) (F 1,32 = 2.18; P > 0.05). Two-way ANOVA revealed that there was a significant effect of genotype on summation of locomotor activity from t = 20 to t = 80 min ( Fig. 2c ) (F 1,32 = 6.74; P < 0.05). Post hoc analysis indicated that DOI increased locomotor activity from t = 20 to t = 80 min in wild-type mice (P < 0.05), but not in mGlu2-KO mice ( Fig. 2c ) (P > 0.05). Post hoc analysis also showed absence of differences in locomotor activity from t = 20 to t = 80 min between vehicle-treated wildtype mice and vehicle-treated mGlu2-KO mice ( Fig. 2c ) (P > 0.05).
Two-way ANOVA indicated that there was a significant effect of DOI treatment on summation of locomotor activity from t = 85 to t = 120 min ( Fig. 2d ) (F 1,32 = 4.22; P < 0.05). Two-way ANOVA revealed that there was not a significant effect of genotype on summation of locomotor activity from t = 85 to t = 120 min ( Fig. 2d ) (F 1,32 = 0.21; P > 0.05). Post hoc analysis indicated that DOI increased locomotor activity in wild-type mice (P < 0.01), but not in mGlu2-KO mice (Fig. 2d) (P > 0.05). Post hoc analysis also showed absence of differences in locomotor activity from t = 85 to t = 120 min between vehicle-treated wild-type mice and vehicle-treated mGlu2-KO mice ( 
Effect of the clozapine on locomotor activity
Two-way ANOVA revealed that there was not a significant effect of clozapine treatment on locomotor activity time course from t = 20 to t = 120 min in wild-type mice ( Fig. 3a) (F 1,10 = 3.55; P > 0.05). Two-way ANOVA revealed that there was a significant effect of clozapine treatment on locomotor activity time course from t = 20 to t = 120 min in mGlu2-KO mice ( Fig. 3b ) (F 1,10 = 20.99; P < 0.01).
Two-way ANOVA also indicated that there was a significant effect of clozapine treatment on summation of locomotor activity from t = 20 to t = 80 min ( Fig. 3c ) (F 1,20 = 7.75; P < 0.05). Similarly, two-way ANOVA revealed that there was a significant effect of genotype on summation of locomotor activity from t = 20 to t = 80 min ( Fig. 3c ) (F 1,20 = 5.53; P < 0.05). Post hoc analysis indicated that clozapine decreased locomotor activity from t = 20 to t = 80 min in mGlu2-KO mice (P < 0.05), but not in wild-type mice ( Fig. 3c ) (P > 0.05). Post hoc analysis also showed absence of differences in locomotor activity from t = 20 to t = 80 min in vehicle-treated mGlu2-KO mice as compared to vehicletreated wild-type mice ( Fig. 3c ) (P > 0.05).
Two-way ANOVA indicated that there was a significant effect of clozapine treatment on summation of locomotor activity from t = 85 to t = 120 min ( Fig. 3d ) (F 1,20 = 8.30; P < 0.01). Two-way ANOVA revealed that there was not a significant effect of genotype on summation of locomotor activity from t = 85 to t = 120 min ( Fig. 3d ) (F 1,20 = 0.08; P > 0.05). Post hoc analysis indicated that clozapine decreased locomotor activity from t = 85 to t = 120 min in mGlu2-KO mice (P < 0.05), but not in wild-type mice (Fig. 3d ) (P > 0.05). Post hoc analysis also showed absence of differences in locomotor activity from t = 85 to t = 120 min in vehicle-treated mGlu2-KO mice as compared to vehicletreated wild-type mice ( 
Effect of the clozapine on MK801-induced hyperlocomotor activity
Two-way ANOVA revealed that there was a significant effect of clozapine treatment on MK801-induced hyperlocomotor activity time course from t = 20 to t = 120 min in wild-type mice ( Fig. 4a ) (F 1,10 = 12.11; P < 0.01). However, two-way ANOVA revealed that there was not a significant effect of clozapine treatment on MK801-induced hyperlocomotor time course from t = 20 to t = 120 min in mGlu2-KO mice (Fig. 4b ) (F 1,10 = 3.49; P > 0.05).
Two-way ANOVA also indicated that there was a significant effect of clozapine treatment on summation of MK801- Wildtype and mGlu2-KO mice were placed in the locomotor chamber and allowed to habituate for 90 min. After habituation, mice were injected with DOI (1.0 mg/kg) or vehicle and locomotor activity was measured for another 120 min (n = 6-12). a, b
The time course of DOI-induced locomotion in 5 min blocks. Time of injection is indicated by arrow. c, d Data summary of the total DOI-induced locomotion as a summation of horizontal activity from t = 20 to t = 80 min (c) and from t = 85 to t = 120 min (d). *P < 0.05, **P < 0.01, ***P < 0.001, Bonferroni's post hoc test of two-way ANOVA. Data are means ± SEM; n.s., not significant induced hyperlocomotor activity from t = 20 to t = 80 min ( Fig. 4c ) (F 1,20 = 12.72; P < 0.01). Two-way ANOVA revealed that there was not a significant effect of genotype on summation of MK801-induced hyperlocomotor from t = 20 to t = 80 min ( Fig. 4c ) (F 1,20 = 3.06; P > 0.05). Post hoc analysis indicated that clozapine decreased MK801-induced hyperlocomotor activity from t = 20 to t = 80 min in wildtype mice (P < 0.05), but not in mGlu2-KO mice (Fig. 4c ) (P > 0.05). Post hoc analysis also showed absence of differences in locomotor activity from t = 20 to t = 80 min in mGlu2-KO mice treated with MK801 and vehicle as compared to wild-type mice treated with MK801 and vehicle ( Fig. 4c ) (P > 0.05). Two-way ANOVA indicated that there was a significant effect of clozapine treatment on summation of MK801-induced hyperlocomotor activity from t = 85 to t = 120 min (Fig. 4d ) (F 1,20 = 8.28; P < 0.01). Two-way ANOVA revealed that there was a significant effect of genotype on summation of MK801-induced hyperlocomotor from t = 85 to t = 120 min (Fig. 4d ) (F 1,20 = 8.04; P < 0.05). Post hoc analysis indicated that clozapine decreased MK801-induced hyperlocomotor activity from t = 85 to t = 120 min in wild-type mice (P < 0.01), but not in mGlu2-KO mice (Fig. 4d) (P > 0.05). Post hoc analysis also showed absence of differences in locomotor activity from t = 85 to t = 120 min in mGlu2-KO mice treated with MK801 and vehicle as compared to wild-type mice treated with MK801 and vehicle (Fig. 4d) (P > 0.05).
Effect of the clozapine on PCP-induced hyperlocomotor activity
Two-way ANOVA revealed that there was a significant effect of clozapine treatment on PCP-induced hyperlocomotor activity time course from t = 20 to t = 120 min in wild-type mice (Fig. 5a ) (F 1,10 = 26.84; P < 0.001). However, two-way ANOVA revealed that there was not a significant effect of clozapine treatment on PCP-induced hyperlocomotor time course from t = 20 to t = 120 min in mGlu2-KO mice (Fig.  5b ) (F 1,10 = 0.084; P > 0.05).
Two-way ANOVA also indicated that there was not a significant effect of clozapine treatment on summation of PCPinduced hyperlocomotor activity from t = 20 to t = 80 min (Fig. 5c ) (F 1,20 = 1.14; P > 0.05). Two-way ANOVA revealed that there was a significant effect of genotype on summation of PCP-induced hyperlocomotor activity from t = 20 to t = 80 min (Fig. 5c ) (F 1,20 = 6.71; P < 0.05). Post hoc analysis showed a trend for reduced PCP-induced hyperlocomotor activity from t = 20 to t = 80 min in wild-type mice treated with clozapine ( Fig. 5c ) (P = 0.062). Post hoc analysis showed absence of differences in PCP-induced hyperlocomotor activity from t = 20 to t = 80 min in mGlu2-KO mice treated with clozapine ( Fig. 5c ) (P > 0.05). Post hoc analysis also showed absence of differences in locomotor activity from t = 20 to t = 80 min in mGlu2-KO mice treated with PCP and vehicle as compared to wild-type mice treated with PCP and vehicle ( Fig. 5c ) (P > 0.05). Wild-type and mGlu2-KO mice were placed in the locomotor chamber and allowed to habituate for 90 min. After habituation, mice were injected with clozapine (1.5 mg/kg) or vehicle followed by MK801 (0.5 mg/kg), and locomotor activity was measured for another 120 min (n = 6). a, b
The time course of MK801-induced locomotion in 5 min blocks. Time of injection is indicated by arrow. c, d Data summary of the total MK801-induced locomotion as a summation of horizontal activity from t = 20 to t = 80 min (c) and from t = 85 to t = 120 min (d). *P < 0.05, **P < 0.01, ***P < 0.001, Bonferroni's post hoc test of twoway ANOVA. Data are means ± SEM; n.s., not significant Two-way ANOVA indicated that there was not a significant effect of clozapine treatment on summation of PCPinduced hyperlocomotor activity from t = 85 to t = 120 min ( Fig. 5d ) (F 1,20 = 1.98; P > 0.05). Two-way ANOVA revealed that there was not a significant effect of genotype on summation of PCP-induced hyperlocomotor from t = 85 to t = 120 min (Fig. 5d ) (F 1,20 = 2.66; P > 0.05). However, post hoc analysis indicated that clozapine decreased PCP-induced hyperlocomotor activity from t = 85 to t = 120 min in wildtype mice (P < 0.05), but not in mGlu2-KO mice (Fig. 5d ) (P > 0.05). Post hoc analysis also showed absence of differences in locomotor activity from t = 85 to t = 120 min in mGlu2-KO mice treated with PCP and vehicle as compared to wild-type mice treated with PCP and vehicle ( Fig. 5d ) (P > 0.05).
Effect of the clozapine on amphetamine-induced hyperlocomotor activity
Two-way ANOVA revealed that there was a significant effect of clozapine treatment on amphetamine-induced hyperlocomotor activity time course from t = 20 to t = 120 min in wild-type mice (Fig. 6a ) (F 1,10 = 10.72; P < 0.01). Two-way ANOVA also revealed that there was a significant effect of clozapine treatment on amphetamineinduced hyperlocomotor time course from t = 20 to t = 120 min in mGlu2-KO mice (Fig. 6b ) (F 1,10 = 5.80; P < 0.05).
Two-way ANOVA indicated that there was a significant effect of clozapine treatment on summation of amphetamineinduced hyperlocomotor activity from t = 20 to t = 80 min (Fig. 6c ) (F 1,20 = 11.57; P < 0.01). Two-way ANOVA also revealed that there was not a significant effect of genotype on summation of amphetamine-induced hyperlocomotor activity from t = 20 to t = 80 min (Fig. 6c ) (F 1,20 = 0.30; P > 0.05). Post hoc analysis indicated that clozapine decreased amphetamine-induced hyperlocomotor activity from t = 20 to t = 80 min in both wild-type (P < 0.05) and mGlu2-KO mice (Fig. 6c) (P < 0.05). Post hoc analysis also showed absence of differences in locomotor activity from t = 20 to t = 80 min in mGlu2-KO mice treated with amphetamine and vehicle as compared to wild-type mice treated with amphetamine and vehicle (Fig. 6c) (P > 0.05). Wild-type and mGlu2-KO mice were placed in the locomotor chamber and allowed to habituate for 90 min. After habituation, mice were injected with clozapine (1.5 mg/kg) or vehicle followed by PCP (7.5 mg/kg), and locomotor activity was measured for another 120 min (n = 6). a, b The time course of PCP-induced locomotion in 5 min blocks. Time of injection is indicated by arrow. c, d Data summary of the total PCP-induced locomotion as a summation of horizontal activity from t = 20 to t = 80 min (c) and from t = 85 to t = 120 min (d). *P < 0.05, **P < 0.01, ***P < 0.001, Bonferroni's post hoc test of two-way ANOVA. Data are means ± SEM; n.s., not significant Two-way ANOVA indicated that there was a significant effect of clozapine treatment on summation of amphetamineinduced hyperlocomotor activity from t = 85 to t = 120 min ( Fig. 6d ) (F 1,20 = 9.86; P < 0.01). Two-way ANOVA revealed that there was a significant effect of genotype on summation of amphetamine-induced hyperlocomotor from t = 85 to t = 120 min (Fig. 6d ) (F 1,20 = 4.44; P < 0.05). Post hoc analysis indicated that clozapine decreased amphetamine-induced hyperlocomotor activity from t = 85 to t = 120 min in mGlu2-KO mice (Fig. 6d) (P < 0.001), but not in wild-type mice (Fig. 6d) (P > 0.05). Post hoc analysis also showed augmented hyperlocomotor activity from t = 85 to t = 120 min in mGlu2-KO mice treated with amphetamine and vehicle as compared to wild-type mice treated with amphetamine and vehicle ( Fig. 6d) (P < 0.01).
Effect of the clozapine on scopolamine-induced hyperlocomotor activity
Two-way ANOVA revealed that there was a significant effect of clozapine treatment on scopolamine-induced hyperlocomotor activity time course from t = 5 to t = 120 min in wild-type mice (Fig. 7a ) (F 1,10 = 5.90; P < 0.05). Two-way ANOVA revealed that there was a significant effect of clozapine treatment on scopolamine-induced hyperlocomotor time course from t = 5 to t = 120 min in mGlu2-KO mice (Fig. 7b ) (F 1,10 = 12.94; P < 0.01).
Two-way ANOVA also indicated that there was a significant effect of clozapine treatment on summation of scopolamine-induced hyperlocomotor activity from t = 5 to t = 80 min (Fig. 7c ) (F 1,20 = 10.01; P < 0.01). Two-way ANOVA revealed that there was not a significant effect of genotype on summation of amphetamine-induced hyperlocomotor activity from t = 5 to t = 80 min (Fig. 7c ) (F 1,20 = 0.76; P > 0.05). Post hoc analysis indicated that clozapine decreased scopolamine-induced hyperlocomotor activity from t = 5 to t = 80 min in both wild-type (P < 0.01) and mGlu2-KO mice (Fig. 7c) (P < 0.01). Post hoc analysis also showed absence of differences in locomotor activity from t = 5 to t = 80 min in mGlu2-KO mice treated with scopolamine and vehicle as compared to wild-type mice treated with scopolamine and vehicle (Fig. 7c) (P > 0.05).
Two-way ANOVA indicated that there was not a significant effect of clozapine treatment on summation of Wild-type and mGlu2-KO mice were placed in the locomotor chamber and allowed to habituate for 90 min. After habituation, mice were injected with clozapine (1.5 mg/kg) or vehicle followed by amphetamine (6.0 mg/kg), and locomotor activity was measured for another 120 min (n = 6). a, b The time course of amphetamine-induced locomotion in 5 min blocks. Time of injection is indicated by arrow. c, d Data summary of the total amphetamine-induced locomotion as a summation of horizontal activity from t = 20 to t = 80 min (c) and from t = 85 to t = 120 min (d). *P < 0.05, **P < 0.01, ***P < 0.001, Bonferroni's post hoc test of twoway ANOVA. Data are means ± SEM; n.s., not significant scopolamine-induced hyperlocomotor activity from t = 85 to t = 120 min ( Fig. 7d ) (F 1,20 = 1.48; P > 0.05). Two-way ANOVA revealed that there was a significant effect of genotype on summation of scopolamine-induced hyperlocomotor from t = 85 to t = 120 min ( Fig. 7d ) (F 1,20 = 2.13; P < 0.05). Post hoc analysis indicated that clozapine decreased scopolamine-induced hyperlocomotor activity from t = 85 to t = 120 min in mGlu2-KO mice (Fig. 7d) (P < 0.001), but not in wild-type mice (Fig. 7d ) (P > 0.05). Post hoc analysis also showed augmented hyperlocomotor activity from t = 85 to t = 120 min in mGlu2-KO mice treated with scopolamine and vehicle as compared to wild-type mice treated with scopolamine and vehicle ( Fig. 7d) (P < 0.01).
Virally mediated over-expression of mGlu2 in the frontal cortex of mGlu2-KO mice does not affect exploratory behavior mGlu2-KO mice received intra-frontal cortical injections of HSV expressing G FP alone or ei ther m Glu2 or mGlu2ΔTM4N together with GFP. Immunofluorescence assays confirmed that the viral vector was injected into the appropriate brain region (Fig. 8a) . Two-way ANOVA revealed that there was not significant effect of viral injection on spontaneous locomotor activity (exploratory behavior) in mGlu2-KO mice (Fig. 8b ) (F 2,38 = 0.96; P > 0.05). One-way ANOVA indicated that there was not a significant effect of viral injection on summation of horizontal activity from t = 5 to t = 30 min in mGlu2-KO mice (Fig. 8c ) (F 2,38 = 0.90; P > 0.05). One-way ANOVA indicated that there was not a significant effect of viral injection on summation of horizontal activity from t = 35 to t = 85 min in mGlu2-KO mice (Fig. 8d ) (F 2,38 = 0.61; P > 0.05).
Virally mediated over-expression of mGlu2 in the frontal cortex of mGlu2-KO mice rescues antipsychotic-like behavior Two-way ANOVA indicated that there was not a significant effect of clozapine treatment on MK801-induced hyperlocomotor activity time course from t = 20 to t = 120 min in mGlu2-KO mice injected with HSV-GFP (Fig. 9a ) (F 1,12 = 1.01; P > 0.05). Two-way ANOVA revealed Wild-type and mGlu2-KO mice were placed in the locomotor chamber and allowed to habituate for 90 min. After habituation, mice were injected with clozapine (1.5 mg/kg) or vehicle followed by scopolamine (2.0 mg/kg), and locomotor activity was measured for another 120 min (n = 6). a, b The time course of scopolamine-induced locomotion in 5 min blocks. Time of injection is indicated by arrow. c, d Data summary of the total scopolamine-induced locomotion as a summation of horizontal activity from t = 5 to t = 80 min (c) and from t = 85 to t = 120 min (d). *P < 0.05, **P < 0.01, ***P < 0.001, Bonferroni's post hoc test of two-way ANOVA. Data are means ± SEM; n.s., not significant that there was a significant effect of clozapine treatment on MK801-induced hyperlocomotor activity time course from t = 20 to t = 120 min in mGlu2-KO mice injected with HSVmGlu2 ( Fig. 9b ) (F 1,14 = 7.42; P < 0.05). Two-way ANOVA indicated that there was not a significant effect of clozapine treatment on MK801-induced hyperlocomotor activity time course from t = 20 to t = 120 min in mGlu2-KO mice injected with HSV-mGlu2ΔTM4 (Fig. 9c ) (F 1,10 = 0.18; P > 0.05). Two-way ANOVA indicated that there was a significant effect of clozapine treatment on summation of MK801-induced hyperlocomotor activity from t = 20 to t = 80 min (Fig. 9d ) (F 1,36 = 4.95; P < 0.05). Two-way ANOVA also revealed that there was not a significant effect of viral injection on summation of MK801-induced hyperlocomotor from t = 20 to t = 80 min (Fig. 9d ) (F 2,36 = 1.48; P > 0.05). Post hoc analysis indicated that clozapine decreased MK801-induced hyperlocomotor activity from t = 20 to t = 80 min in mGlu2-KO mice stereotaxically injected with HSV-mGlu2 (P < 0.05), but not with HSV-GFP (P > 0.05) or HSV-mGlu2ΔTM4 (P > 0.05) (Fig. 9d) .
Two-way ANOVA indicated that there was not a significant effect of clozapine treatment on summation of MK801-induced hyperlocomotor activity from t = 85 to t = 120 min (Fig. 9e ) (F 1,36 = 0.17; P > 0.05). Two-way ANOVA revealed that there was not a significant effect of viral injection on summation of MK801-induced hyperlocomotor from t = 85 to t = 120 min (Fig. 9e ) (F 2,36 = 2.28; P > 0.05). Post hoc analysis indicated that clozapine did not affect MK801-induced hyperlocomotor activity from t = 85 to t = 120 min in mGlu2-KO mice stereotaxically injected with HSV-GFP (P > 0.05), HSV-mGlu2 (P > 0.05), or HSV-mGlu2ΔTM4 (P > 0.05) (Fig. 9e) .
Discussion
We tested the extent to which mGlu2 receptor expression is necessary for the effects of the atypical antipsychotic clozapine on prevention of hyperlocomotor activity induced by different families of psychoactive substances-these included the dissociative drugs MK801 and PCP, the stimulant drug amphetamine, and the deliriant drug scopolamine. We show that the inhibitory effect of clozapine treatment on either MK801-induced or PCP-induced hyperlocomotor activity was observed in wild-type mice, but was absent in mGlu2-KO mice. Notably, this need for mGlu2 receptor expression to induce clozapine-dependent antipsychotic-related effects was not observed in mice injected with amphetamine or Fig. 9 Virally mediated over-expression of mGlu2, but not mGlu2ΔTM4, in the frontal cortex of mGlu2-KO mice rescues the effect of clozapine on MK801-induced hyperlocomotor activity. a-e HSV-GFP, HSV-mGlu2, or HSV-mGlu2ΔTM4 were injected into the frontal cortex of mGlu2-KO mice. Animals were placed in the locomotor chamber and allowed to habituate for 90 min. After habituation, mice were injected with clozapine (1.5 mg/kg) or vehicle followed by MK801 (0.5 mg/kg), and locomotor activity was measured for another 120 min (n = 7-8). a-c The time course of MK801-induced locomotion in 5 min blocks. Time of injection is indicated by arrow. d, e Data summary of the total MK801-induced locomotion as a summation of horizontal activity from t = 20 to t = 80 min (d) and from t = 85 to t = 120 min (e). *P < 0.05, **P < 0.01, ***P < 0.001, Bonferroni's post hoc test of two-way ANOVA. Data are means ± SEM; n.s., not significant scopolamine. Additionally, virally mediated over-expression of mGlu2 in the frontal cortex of mGlu2-KO mice was sufficient to rescue the preventive effect of clozapine administration on MK801-induced hyperlocomotor activity.
Animals with a high level of anxiety or very low levels of activity tend to remain in the periphery of a testing enclosure (Weisstaub et al. 2006) . Conversely, animals with low levels of anxiety generally spend greater amounts of time in the center Bunprotected^area. Thus, measures of total distance covered during locomotion are used as an index of exploratory activity, while the proportion of time spent in the center of the arena is taken as a measure of anxiety. In agreement with previous reports (Morishima et al. 2005 ), our data demonstrate that exploratory activity (total distance) was increased in mGlu2-KO mice as compared to wild-type littermates. We also found that mGlu2-KO mice explored the center portion of the environment (as a percentage of total exploratory time) more than their control littermates. These findings suggest that global disruption of mGlu2 receptor-dependent signaling reduces inhibition in conflict anxiety paradigms.
Previous reports have described that the 5-HT 2A/2C receptor agonist DOI induces opposing effects on locomotor activity in mice (Halberstadt et al. 2009 ). Thus, low doses of DOI increase locomotor activity, an effect absent in 5-HT 2A -KO mice, whereas higher doses of DOI decrease locomotor activity in a manner prevented by the 5-HT 2C antagonist SER-082. These changes in locomotor activity were observed in mice that were placed in the open field 15 min after treatment with DOI (Halberstadt et al. 2009 ). We show that, as expected, exploratory activity correlates negatively with time of exposure: exploratory behavior was almost null after 60 min of exposure to the open field. Nevertheless, DOI administration (1.0 mg/kg) injected 90 min after habituation to the open field still moderately increased locomotor activity in wild-type mice. This further demonstrates that activation of the 5-HT 2A receptor increases locomotor activity in rodent models. Additionally, this effect of DOI augmenting locomotor activity and exploratory behavior was not observed in mGlu2-KO mice, which further suggests that mGlu2 plays a fundamental role in modulating 5-HT 2A receptor-dependent phenotypes. Although post hoc analysis showed absence of differences in locomotor activity between vehicle-treated wild-type mice and vehicle-treated mGlu2-KO mice (see Fig. 2c, d) , an alternative explanation for the absence of effect of DOI administration on locomotor activity in mGlu2-KO mice as compared to mGlu2-KO mice treated with vehicle may be related to the trend toward increased exploratory behavior in mGlu2-KO mice together with the relatively moderate effect of DOI on locomotor activity.
Our current findings suggest that, as expected, administration of the atypical antipsychotic clozapine decreases the hyperlocomotor activity induced by the psychoactive drugs MK801, PCP, amphetamine, and scopolamine in wild-type mice. Because clozapine binds with high affinity to the 5-HT 2A receptor, and with lower affinity to dopamine D 2 and other monoaminergic receptors (Miyamoto et al. 2012) , we and others have previously established the lowest dose of clozapine that reduces MK801-induced hyperlocomotor activity in mice via interaction with the 5-HT 2A receptor (Fribourg et al. 2011; Schmid et al. 2014) . Thus, we showed that pretreatment with clozapine (1.5 mg/kg) significantly decreases MK801-induced hyperlocomotor activity in wild-type mice, but not in 5-HT 2A -KO littermates (Fribourg et al. 2011) . Administration of higher doses of clozapine (10 mg/kg) is able to suppress MK801-induced hyperlocomotor activity in both wild-type and 5-HT 2A -KO mice (Fribourg et al. 2011) . Our data here showing absence of effect with low doses of clozapine (1.5 mg/kg) on locomotion in wild-type mice are consonant with previous reports suggesting that low doses of clozapine (below 3 mg/kg) do not significantly decrease locomotion in mice (McOmish et al. 2012) . Importantly, our data also suggest the pivotal finding that the effect of intraperitoneal administration of clozapine (1.5 mg/kg) on hyperlocomotor activity induced by the dissociative drugs MK801 or PCP is significantly diminished in mice with global disruption of mGlu2 receptor-dependent signaling. However, this effect of clozapine treatment on suppression of hyperlocomotor activity was present when mGlu2-KO mice were injected with either amphetamine or scopolamine. Together, these data suggest that expression of mGlu2 receptor is necessary for the 5-HT 2 A receptor-dependent effects of clozapine on hyperlocomotor activity induced by dissociative drugs whose primary action relies on disruption of glutamate neurotransmission.
A potential explanation for the effects of clozapine treatment on hyperlocomotor activity in mGlu2-KO mice injected with either amphetamine or scopolamine may be related to differences in specific signaling pathways or brain regions affected by disruptions of dopaminergic and cholinergic neurotransmission. Nonetheless, the precise molecular mechanism that results in differential modulation of hyperlocomotor activity phenotypes will require further investigation. We also found that the hyperlocomotive effect of amphetamine and scopolamine on hyperlocomotor activity was increased in mGlu2-KO mice as compared to wild-type controls. This particular phenotype, which was observed approximately 1 h after administration of either amphetamine or scopolamine, may be influenced by the same mechanism underlying the augmented exploratory behavior observed in mGlu2 null-mutant mice that we speculate might be related to diminished modulation of glutamatergic signal upon deletion of mGlu2 expression. Additional work will be required to test the extent to which mGlu2 receptor-dependent signaling is needed for clozapine-dependent antipsychotic-like effect in additional behavioral models related to cognition, memory processing, and sensorimotor gating. Similarly, considering that clozapine presents unique characteristics in both clinical efficacy and pharmacological properties at the 5-HT 2A receptor (Meltzer 2013) , further work will be needed to clarify whether other atypical antipsychotic drugs, such as olanzapine and risperidone, possess similar properties to those of clozapine targeting the 5-HT 2A receptor.
The 5-HT 2A receptor is widely expressed in CNS structures involved in cognition, perception, and mood, such as the cerebral cortex, ventral striatum, and ventrobasal thalamus Jakab and Goldman-Rakic 1998; Lopez-Gimenez et al. 2001; Weber and Andrade 2010) . Using a Cre-loxP system to drive selective cortical expression of the 5-HT 2A receptor, our previous findings suggested that cortical glutamatergic, but not subcortical, 5-HT 2A receptor expression, is necessary to mediate the signaling pattern and psychosis-like behavioral effects of hallucinogenic 5-HT 2A receptor agonists (Gonzalez-Maeso et al. 2007 ). It has also been shown that mGlu2 receptor is located both postsynaptically as well as presynaptically in glutamatergic terminals in the frontal cortex (Neki et al. 1996; Ohishi et al. 1998; Moreno et al. 2016) . However, the role of cortical mGlu2 in the therapeutic-related behavioral effects of clozapine treatment remained poorly characterized. Using a virally mediated over-expression approach, our data suggest that frontal cortex neurons may be unique in their capacity to trigger the specific signaling pathways that prevent hyperlocomotor activity induced by dissociative drugs. Thus, our data show that the effect of clozapine on prevention of MK801-induced hyperlocomotor activity is rescued in mGlu2-KO mice stereotaxically injected with HSV-mGlu2 in the frontal cortex, an effect not observed in mGlu2-KO mice stereotaxically injected with HSV-GFP. Although these data suggest that postsynaptic mGlu2 is necessary for the effects of clozapine treatment on prevention of hyperlocomotor activity induced by MK801 treatment, further work will be needed with different viral vectors expressing mGlu2 under the control of different promoters to rescue mGlu2 expression at either postsynaptic or presynaptic sites in order to provide a better understanding of the cell type and neural circuits responsible for these antipsychotic-related phenotypes.
Family A GPCRs, such as serotonin, norepinephrine, and opioid receptors, were assumed to function as strict monomers. This observation is supported by previous findings that showed functional receptor-G protein coupling of a single family A GPCR, such as β 2 -adrenergic receptor (Whorton et al. 2007 ), rhodopsin (Whorton et al. 2008) , or the μ-opioid receptor (Kuszak et al. 2009 ), reconstituted in nanodiscs. This is consistent with recent X-ray crystal (Rasmussen et al. 2011 ) and cryo-EM GPCR-G protein complex (Thomsen et al. 2016; Liang et al. 2017) structures. Nevertheless, many instances of homomerization and heteromerization have been reported among different GPCR f a m i l i e s , d e m o n s t r a t i n g th a t G P C R h o m o -a n d heteromerization dramatically affect receptor trafficking, pharmacology, and function (Ward et al. 2013; Ferre et al. 2014) . Most of these studies, however, have been reported in heterologous expression systems (González-Maeso 2011; Gonzalez-Maeso 2014) , and hence only a limited number of reports can support the conclusion that GPCR complexes may play a role in physiological or behavioral phenotypes in rodent models. Our previous findings suggest that 5-HT 2A and mGlu2 receptors are assembled as a GPCR heteromeric complex (Gonzalez-Maeso et al. 2008; Fribourg et al. 2011; Moreno et al. 2012; Baki et al. 2016; Moreno et al. 2016 ). This was demonstrated based on the use of biophysical approaches such as co-immunoprecipitation, bioluminescence resonance energy transfer (BRET), and fluorescence resonance energy transfer (FRET) in mammalian cell tissue culture. The physiological validity of these findings obtained in heterologous expression systems was corroborated by ex vivo assays, such as co-immunoprecipitation and subcellular proximity at the electron microscopy level in mouse and postmortem human frontal cortex. Although these findings support that 5-HT 2A and mGlu2 form part of the same protein complex, whether this GPCR heteromer plays a role in the behavioral phenotypes induced by antipsychotics remains unclear.
Within this context, our previous findings suggested that three residues located at the intracellular end of transmembrane four (TM4) are responsible for the location of the mGlu2 receptor in close proximity to the 5-HT 2A receptor in heterologous expression systems ). This was assessed by testing receptor heteromerization in living mammalian cells co-expressing the 5-HT 2A receptor together with mGlu2 or different mGlu2/mGlu3 chimeric constructs, including mGlu2ΔTM4N . Considering that HSV-mediated over-expression of mGlu2, but not the mGlu2ΔTM4N chimeric construct, in the frontal cortex of mGlu2-KO mice rescued the antipsychoticrelated properties of clozapine, these data suggest that frontal cortex GPCR heteromeric assembly between 5-HT 2A and mGlu2 receptors may be necessary for at least some of the antipsychotic-related behavioral effects of clozapine. An alternative, although not mutually exclusive, explanation for the absence of effect of clozapine on MK801-induced hyperlocomotor activity observed in mGlu2-KO mice stereotaxically injected with either HSV-GFP or HSV-mGlu2ΔTM4N, but not with HSV-mGlu2, might be related to molecular mechanisms involving the capability of the mGlu2ΔTM4N construct to functionally interact with other GPCRs or signaling proteins that affect 5-HT 2A receptor expression, subcellular localization, trafficking, and/or signaling, as well as the stoichiometry of these neurotransmitter receptors. Further work is therefore necessary to fully define whether a physical interaction between 5-HT 2A and mGlu2 is needed for their pharmacological and behavioral crosstalk in whole animal model systems.
It is well recognized that sex differences have an impact on mental health and, in particular, on the course of schizophrenia (Crawford and DeLisi 2016) . Considering that the current analysis focuses on male mice, future work should extend these findings to females to determine the generalizability and specificity of basic signaling mechanisms underlying hallucinogen and antipsychotic drug action.
In summary, we showed that absence of mGlu2 receptordependent signaling differentially affects the response to drugs bearing distinct mechanism of action yet commonly used as models of psychosis in mice. Additionally, we demonstrated that the effect of pretreatment with clozapine on hyperlocomotor activity induced by the dissociative drugs MK801 and PCP is reduced in mGlu2-KO mice, whereas clozapine administration was able to reduce hyperlocomotor activity induced by amphetamine and scopolamine in both mGlu2-KO and wild-type mice. Our data also suggest that virally mediated restoration of mGlu2 expression in the frontal cortex of mGlu2-KO mice rescues the repressive effect of clozapine treatment on MK801-induced hyperlocomotor activity. Together, these findings extend our knowledge of the role of mGlu2 receptor-dependent signaling in antipsychoticrelated behavioral phenotypes in rodent models. 
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